academics undergraduate course description degree plan graduate course description degree plan Blue & Gold faculty/staff faculty Bashir, Sajid Beller, Nicholas Bhattacharya, Apu Castro, Mauro Chi, Xiaoliu Gonzalez-Garcia, Maribel Hays, Thomas Liu, Jingbo Louise Martino, Rochelle Moehring, Gregory Retirees staff Barrera, Ricky Clancy, Dan Thomas, Ronny Zamora-Rubio, Deanna information calendar Department University general information mission statement Garland Lecture Welch Lecture students current undergraduate graduate prospective undergraduate graduate former contact us admin. assistant deparment chair graduate advisor

 

Ph.D. Organic Chemistry, University of Texas at Austin: 1982
M.S. Chemistry, I. I.T. Kanpur, India: 1976
B.S. Chemistry, Calcutta University, India: 1974

Office: N205
Phone: (361) 593-2664
Mailing Address: 920 W. Santa Gertrudis
Kingsville, TX 78363
E-mail address: kfab002@tamuk.edu

Professional Experience

2008-Present   Associate Professor, Texas A&M Kingsville
2007-2008       Senior Vice President. Dr. Reddy’s Laboratories, India.
2006-2007       Vice President, Head of Global Research & Development; Dr. Reddy’s Laboratories, India.
2004-2006       Tenured, Associate Professor
1999-2004       Assistant Professor, Texas A&M University, Kingsville.
1997-1999       Group Leader, Bristol Myers Squibb, Central Process Research
1995-1997       Lead Chemist; Innovator Group, Hoechst.
1994-1995       Staff Chemist, Hoechst-Celanese.
1990-1994       Senior Research Chemist, Hoechst-Celanese.
1988-1990       Research Fellow, Process Research and Development, Merck & Co., Inc.
1983-1988       Senior Research Chemist, Process Research and Development, Merck & Co., Inc.

Curriculum Vitae

Student Presentations

Research Group News Flash

10-02-2004     Pharm Tech - In the Field - Production Process Increases Productivity
07-06-2004     Bridges program offers students road to success
06-15-2004     Professor to speak at annual symposium
.09-05-2003. Texas A&M University-Kingsville paves way to Ph.D.s (Corpus Christi Caller Times)
09-03-2003     Chemistry Bridges to Doctoral Grant
10-14-2002     Professor Simplifies Tylenol Production (Corpus Christi Caller Times)
08-01-2002     A&M-Kingsville has partnership with drug industry (Corpus Christi Caller Times)
07-23-2001     Education Concentrates (Chemical & Engineering News)
06-21-2001     Graduate Students Intern at Bristol-Meyers Squibb (TAMUK Press Release)
11-01-1999     Renowned chemist sharing his vision (Corpus Christi Caller Times)

Dr. Bhattacharya's Organic and Environmental Research

Meet Dr. Bhattacharya's Research Group

Current Students Former Students

Consultant: 

A. Advisory Board for the Clinton Foundation HIV/AIDS Initiative (CHAI)

B. Member of the National Academies’ Chemical Sciences Roundtable (CSR). This is a committee of advisors that reports its recommendation of the directions of US Science to the US Congress and the President.

C. Member: Panel of Drug Evaluators for Current Drugs (CD). Responsible for the evaluation of drugs, which are being launched worldwide under FDA guidelines.

D. Scientific Process Advisor:

1. Dr Reddy’s Laboratories. Hyderabad, India.
2. PHARM-ECO A Johnson Matthey Company
3. Texas Bio Technology.
4. Bristol Myers Squibb Pharmaceutical Co.
5. Boehringer-Ingelheim Pharmaceutical.
6. Johnson & Johnson Pharmaceutical Research & Development.
7. Ambion.
8. National Advisory Committee, Osmania University, India.

E. Consultant:

1. Senator Kay Bailey Hutchison’s List of Designated Expert in Environmental Chemistry .
2. Corpus Christi Regional Economic Development Corporation

F. Advisory Board Member: Chembiotek, India.

G. Advisor: NIH: SSS-L study section, SBIR/STTR applications

Doctoral Work:
University of Texas at Austin. Asymmetric induction in carbon-carbon bond forming reactions. Kinetic resolutions. Chiral Diels Alder reaction. Asymmetric synthesis of natural product.

Current Research:

Pharmaceutical Process Research and Development.

Process chemistry, the practice of scaling up chemical production from gram and kilograms to thousands of gallons while always of vital importance, has lately become a highly visible enterprise in the pharmaceutical sector. In the pharmaceutical industry, once the medicinal chemist defines the target molecule, the process chemist finds the most efficient, economical and safe route to make the molecule and its analogues. We have established collaborative programs with several leading pharmaceutical companies (e.g. Bristol-Myers Squibb Pharmaceuticals Research Institute, Johnson &Johnson, Texas BioTechnology and Pharmeco) whereby the research students are be involved in identifying and solving process related problems and issues of potential mutual interest. This involves synthesizing initial quantities of drug candidates using the existing-route as well as improving the existing synthesis, possibly following a completely different strategy from the medicinal route so that it can be scaled up for commercial production.

Green Chemistry

Environmentally Benign Processes in Organic Synthesis.

Over the past few years significant amount of research activities in the chemical community have been directed towards the development of new technologies and methodologies for environmentally benign processes. This area of chemistry has received extensive attention and is often referred to as "green chemistry". "Green chemistry" focuses on the design, manufacture, and use of chemicals and processes that have little or no pollution potential or environmental risk and are both economically and technologically feasible. The principle of green chemistry can be applied to broad areas of chemistry including synthesis, catalysis, reaction conditions, separations, analysis and monitoring. Green Chemistry differs from conventional chemistry in several different categories including nature of starting materials, reagents, reaction conditions and target molecule. The scope of Research and Development in this area is enormous. We intend to concentrate on the following specific areas of chemistry.

• Solvent Minimization
• Reactions on Zeolite as Solid Support: Waste-free Catalytic Technology
• Organic Reactions in Water.
• Atom-Economy
• Energy conservation: Application of Microwave and Sonication in Organic Synthesis
• Chiral Phase-Transfer Catalysis.

INDUSTRIAL EXPERIENCE

Senior Vice President, Global Head of Research & Development; Active Pharmaceutical Ingredient (A.P.I.) Dr. Reddy’s Laboratories:

Responsibilities:

The responsibilities as the Vice President in the world-wide Active Pharmaceutical Ingredient (API) Business in Dr Reddy’s Laboratories R&D function across Asia, Europe and USA include the following:

• Provide leadership and strategic direction for the global R&D (consisting of more than 700 Ph.D. Chemists and Engineers) and serve on senior R&D staff that is responsible for ensuring effective and innovative product development.
• Direct the activities of multiple project team leaders, pilot pharmaceutical production and chemistry/pharmaceutical services throughout the API and Generics product organization.
• Demonstrate a wealth of scientific, business and cGMP experience in pharmaceutical process development.
• Work in a strongly collaborative and collegial fashion with peers in engineering, formulation and preclinical/pharmacology disciplines to develop novel products involving the release of therapeutic products such as biologics, drugs and other agents.
• Actively participate in the preparation and analysis of the company’s strategic direction, tactical operating plans and new portfolio plan for product development.
• Play a key role in managing the intellectual property output of the R&D group and serve on the world-wide patent portfolio management committee.
• Drive projects to ensure the achievement of product development timelines, which are consistent with corporate objectives, ensuring the highest quality control and output standards.
• Establish and maintain an adequate organizational structure and resources to ensure devices are designed and produced in compliance with applicable federal and international regulations/standards.
• Act as a technical advisor/consultant to senior management as well as multi-disciplinary project teams and other functional areas interfacing with key marketing/sales personnel as well as interfacing with physician customers and business development.
• Team building including hiring of people, their development and motivation from business perspectives while meeting forecasted costs and deliverables maintaining competitive advantage worldwide with cutting edge technology.

Merck.

• Discovered and developed novel silicon mediated quinone oxidation of aza-steroids successfully implemented for the production of PROSCARTM / PROPECIATM and other benign prostatic hypertrophy (BPH)-candidates.
• Process Research and Development designing novel, practical and cost-effective synthesis of drug candidates from bench scale to commercialization.
• Introduced efficient chiral phase-transfer technology to prepare either enantiomer of the drug candidate L-644, 711.

Hoechst.

• Devised and devoloped a unique amphoteric copolymer derived from vinylpyridine and acetoxystyrene.
• Discovered and developed a waste-free synthesis of chiral ibuprofen via unprecedented diastereoreversal.
• Discovered and developed a synthesis of D-p-hydroxyphenylglycine via a novel crystallization induced asymmetric transformation.
• Identified and developed a new synthesis of 2-alkyl indanones.
• Devised and developed a synthesis of cromolyn sodiumTM
• Identified and developed a novel synthesis of 4-quinazolinones as pharmaceutical intermediates.
• Involved in the development from bench scale to commercialization of a 20-step synthesis of Gd/Lu Texaphyrin, agent for MRI imaging, photosensitizer and photodynamic therapy of cancer.

ACADEMIC EXPERIENCE

Texas A&M Kingsville.

• Developed one of the most successful and unique MS programs in Chemistry, based on Industry-University Collaboration in USA.
• Developed a novel surfactant mediated waste-free “Green Technology”
• Developed a “green” economic one-step synthesis of Acetaminophen™ (TylenolÒ).

PUBLICATIONS / PATENTS / PRESENTATIONS

I     Peer Reviewed Published Manuscripts

• "Asymmetric Induction, Nucleophilic Addition to a Chiral Glyoxylate Ester", Whitesell, J. K.; Bhattacharya, A. ; and Henke, K., J. Chem. Soc. Chem. Commun., 988-89 (1982).
• "Asymmetric Induction. Ene Reactions of a Chiral Glyoxylate Ester", Whitesell, J. K.; Bhattacharya, A.; Aguilar, D. A.; and Henke, K., J. Chem. Soc. Chem. Commun., 17, 989-90 (1982)
• "A Glimpse Towards Asymmetric Induction", Bhattacharya, A., Diss. Abstr. Int. B, 43 (12, pt. 1), 3980 (1983)
• "Asymmetric Induction. Reduction, Nucleophilic Addition to and Ene Reaction of Chiral Alpha-Keto Esters", Whitesell, J. K.; Bhattacharya, A.; and Deyo, D., J  Chem. Soc. Chem. Commun., 15, 802 (1983)
• "Efficient Catalytic Asymmetric Alkylations. 2. Chiral Robinson Annulations via Phase-Transfer Catalysis", Bhattacharya, A.; Dolling, U.-H.; Grabowski, E. J. J.; Karady.; Ryan, K. M.; Weinstock, L. M., Angew. Chem., 98, 442-443 (1986)
• "Asymmetric Induction in the Ene Reaction of a Glyoxylate Ester of S-Phenyl Menthol", Whitesell, J. K.; Bhattacharya, A.; Chen, H. H.; Deyo, D.; James, D.; and Liu, C. L., Tetrahedron, 42 (11), 2993-3001 (1986).
• "Efficient Asymmetric Alkylations via Chiral Phase-Transfer Catalysis: Applications and Mechanism", Dolling, U.-H.; Hughes, D. L.; Bhattacharya, A.; Ryan, K. M.; Karady, S.; Weinstock, L. M.; and Grabowski, E. J. J., In: Starks, C. M., Editor, "Phase Transfer Catalysis; New Chemistry, Catalysts, and Applications, Chapter 7", ACS  Symp. Ser., 326, 67-81 (1987).
• "Efficient Asymmetric Alkylations via Chiral Phase-Transfer Catalysis. A Novel Dual Catalysis." Dolling, U.-H.; Hughes, D. L.; Bhattacharya, A.; Ryan, K. M.; Karady, S.; Weinstock. L. M.; Grenda, V. J.; and Grabowski, E. J. J., Catalysis of Organic Reactions, [edited by Paul N. Rylander, Hatedd Greenfield and Robert L. Augustine], 33, 65-86 (1988).
• "Silylation-Mediated Oxidation of 4-Aza-3-Ketosteroids with DDQ Proceeds via DDQ-Substrate Adducts", Bhattacharya, A.; DiMichele, L. M.; Dolling, U.-H.; Douglas, A. W.; and Grabowski, E. J. J.,  J. Am. Chem. Soc., 110, 3318-19 (1988).
• "DDQ Oxidation of Silyl Enol Ethers to Enones Proceeds via DDQ-Substrate Adducts", Bhattacharya, A.; DiMichele, L. M.; Dolling, U.-H.; Grabowski, E. J. J.; Grenda, V. J., J. Org. Chem., 54,6118-6120 (1989).
• "Silicon Assisted Quinone Oxidations Proceeds via Quinone-Substrate Adducts". Merck Speakers Program Brochure 1989-1990.
• "Proscar ®" Merck Index, eleventh edition, 7888, 1989.
• "Oxidation of 4-Aza-3-Ketosteroids". Bhattacharya, A., Centennial Year Edition, MSDRL Selected Publications.
• "Acylimidazolides as Versatile Synthetic Intermediates for the Preparation of Sterically Congested Amides and Ketones: A Practical Synthesis of Proscar" Bhattacharya, A.; Williams, J. M.; Amato, J. S.; Dolling, U.-H.; and Grabowski, E. J. J., Synthetic Communications 30(17), 2683-2690, 1990.
• "Crystallization Induced Asymmetric Transformation: Synthesis of D-p-Hydroxyphenylglycine" Bhattacharya, A.; Aruallo-Mcadams, C.; and Meier, M. B., Synthetic Communications, 24(17), 2449-2459, 1994.
• "Methyl Glyoxylate" Book Chapter, Encyclopedia of Reagents for Organic Synthesis (EROS), Bhattacharya, A.1994.
• "Phenmenthyl Glyoxylate" Book Chapter, Encyclopedia of Reagents for Organic Synthesis (EROS),  Bhattacharya, A. 1994.
• “Preparation of Acrylophenones and 2-Alkyl Indanones Utilizing Hexamethylenetetramine as an Inexpensive Mannich Reagent” Synthetic Communications, 26(9), 1775-1784 (1996).
• “Environmentally Friendly Solvent-Free Processes: Application of a Novel Surfactant Induced Dual Catalysis in Henry Reaction” Organic Process Research Development” 7, 3, 254-258, 2003.
• “Temperature Selective Diastereo-Recognition (TSD): Enantiomeric Ibuprofen via Environmentally Benign Selective Crystallization”. Organic Process Research Development” 7, 5, 717, 2003.
• “Benzoin Condensation: Monitoring a Chemical Reaction by High Pressure Liquid Chromatography”. Journal of Chemical Education, 81, 7 1020-2, 2004.
• “An Efficient Conversion of Nitriles to Amides: Application in the Synthesis of N,N-Diethyl-p-toluamide (DEET™). Tetrahedron Letters 47, 505, 2006.
• “Surfactant-Mediated Solvent-Free Dealkylative Cleavage of Ethers and Esters and Trans-Alkylations under Neutral Conditions” Tetrahedron Letters 47, 565, 2006.
• “One-Step Reductive Amidation of Nitro-Arenes: Application in the Synthesis of Aceaminophen™)” Tetrahedron Letters 47, 1861, 2006.
• “Eco-friendly reductive acetamidation of arylnitro compounds by thioacetate anion through in situ catalytic re-generation: application in the synthesis of acetaminophenTM”
• Tetrahedron Letters 47, 3221, 2006.
• “Remarkable Solvent Effect in Barton-Zard Pyrrole Synthesis: Application in an Efficient One-Step Synthesis of Pyrrole Derivatives”. Tetrahedron Letters, 47, 31, 5421,2006.
• “ Pseudo-Enzymatic Catalyst-Substrate Interactions in Ion-Pair Mediated Chiral Phase Transfer Catalysis”. Tetrahedron Letters 47, 31, 5581, 2006.
• “An Efficient Electrophilic N-Amination Utilizing in situ Generated Chloramine Under Phase Transfer Conditions”. Tetrahedron Letters 47, 30, 5341, 2006.
• “Preparing the Next Generation of Research Scientists” American Chemical Society: Petroleum Research Fund Publication, 2006.
• “An Improved Process for Repaglinide via an Efficient and One Pot Process of (1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butan-1-amine - A Useful Intermediate”. CHIMIA International Journal for Chemistry, Volume 60, Number 9, pp. 593-597(5), September 2006.
• “Substrate Modification Approach to Achieve Efficient Resolution: Didesmethylcitalopram-A Key Intermediate for Escitalopram" Organic Process Research Development 11(2),  289-292, 2007.
• “An Efficient and Impurity-Free Process for Telmisartan: An Antihypertensive Drug”. Organic Process Research & Development, 11(1),  81-85, 2007.
• “Efficient synthesis of (1R)-[3,5-bis (trifluoromethyl) phenyl] ethanol; a key intermediate for aprepitant, an NK-1 receptor antagonist”. Synthetic Communications. 37: 3439–3446, 2007.
• “(S)-3-(Aminomethyl)-5-methylhexanoic acid (Pregabalin)”. Acta Cryst. Section C, C63, o306±o308, 2007.
• “An Alternative Approach to Achieve Enantiopure (3S)-4-Benzyl-3- (4-fluorophenyl)morpholin-2-one: A Key Intermediate of Aprepitant, an NK1 Receptor Antagonist” Organic Process Research & Development. 11(3), 455-457, 2007.
• “Effect of Solvent on Stereoselectivity in Pd-C (Type-39K) Catalyzed
• Hydrogena-tion of Methyl 3-oxo-4-aza-5-α-androstene-17-carboxylate- A
• Key Intermediate for Finasteride and Dutasteride”. Organic Process Research & Development, 11(5); 889-891, 2007.
• "An Alternate Route to 2-Amino-3-Nitro-5-Bromo Picoline: Regioselective Pyridine Synthesis via 2-Nitramino Picoline Intermediate". Organic Process Research & Development, 11(5); 885-888. 2007. [Top ten most downloaded paper in 2007]
• “An Improved Synthesis of Rimonabant: Anti-obesity Drug” Organic Process Research & Development, 11(5),  910-912, 2007. [Top ten most downloaded paper in 2007]
• “A convergent approach to the synthesis of aprepitant: A potent human NK-1 receptor antagonist” Tetrahedron Letters. 48, 8001–8004, 2007.
• “Total synthesis of (-)-galanthamine hydrobromide”. Abstracts of Papers, 234th ACS National Meeting, Boston, MA, United States, August 19-23, 2007,    
• “Boric Acid Cataylyzed Amidation in the synthesis of Active Pharmaceutical Ingredients” Organic Process Research & Development, 11(6); 1065-1068, 2007.
• “Boric Acid: An Efficient and Environmentally Benign Catalyst for
• Transesterification of _-Keto Esters” 49, 106-109, Tetrahedron Letters. 2008.
• “An Expeditious Synthesis of Ramipril: an Angiotensin Converting Enzyme (ACE) Inhibitor#” Synthetic Communications 38(11),  1737-1744, 2008.
• “An Investigation on Key Parameters That Influence the Resolution of Omeprazole Sodium†” Organic Process Research & Development, 12(1),  66-68. 2008.
• “An alternative total synthesis of (-)-galanthamine hydrobromide” Synthetic Communications 38: 2138–2149, 2008.
• “Synthesis of Rimonabant Regioisomer” Monatshefte fur Chemie - Chemical Monthly, 139(9),  1091-1093, 2008.
• “A Novel Synthesis of Fosphenytoin: Anti-convulsant Prodrug” Synthetic Communications 38(17),  2950-2957, 2008.
• “A Non-infringing Synthesis of Simvastatin: HMG-CoA Reductase Inhibitor” Synthetic Communications 2008 (in press).
• “An Alternative Synthesis of Tadalafil: PDE5 Inhibitor” Synthetic Communications, 38(23),  4265-4271, 2008.
• "Reaction of Finasteride Intermediate with Benzeneseleninic Anhydride: An In-depth Study" Industrial & Engineering Chemistry Research 47(23),  9201-9205, 2008.
• “An improved process for eszopiclone: anti-insomnia agent” Organic Communications. 1(2), 33-38, 2008.
• “Borid acid catalyzed environmentally benign amidation and esterification processes in the synthesis of active pharmaceutical ingredients”.  Abstracts of Papers, 236th ACS National Meeting, Philadelphia, PA, United States, August 17-21, 2008.
• “Synthesis of quinoline analogs. Search for antimalarial agents”. Monatshefte fuer Chemie. 139(2),  179-181, 2008. 
• “Efficient Synthesis of Olmesartan Medoxomil, an Antihypertensive Drug” Synthetic Communications, 39 (2): 291–298, 2009.
• “Novel synthesis of fosphenytoin. anti-convulsant prodrug”. Synthetic Communications. 39(4), 748.  2009.
• Ab initio structure determination of anhydrous sodium alendronate from laboratory powder X-ray diffraction data . Journal of Pharmaceutical Sciences 98(6), 2113-2121, 2009. 
• Preparative Chromatography Technique in the Removal of Isostructural Genotoxic Impurity in Rizatriptan: Use of Physicochemical Descriptors of Solute and Adsorbent . Organic Process Research & Development, ACS ASAP. 2009.
• “Green Technologies in the Generic Pharmaceutical Industry” An invited Book Chapter “Green Chemistry in the Pharmaceutical Industry” to be published, John Wiley & Sons, 2009.
• “Green Chemistry in Drug Discovery and Process Research” an invited review article to be published in Current Opinion in Drug Discovery & Development. Manuscript submitted.

II. Patents

• "Preparation of an Enantiomer of a Substituted Fluorenyloxy Acetic Acid", Application No: 06/766,376, Publication No. U.S. Patent 4605760, Application Date: 1985-08-16, Publication Date: 1986-08-12.
• "Enantiomers of a Substituted Fluorenyloxy Acetic Acid": Application No: EP19850112149 19850925, Publication No: European Patent. EP-176947, Publication Date: 1986-04-09.
• "Preparation of Enantiomers of a Substituted Fluorenyloxy Acetic Acid": Application No: 06/656,577, Publication No U.S. Patent 45857357, Application Date: 1984-10-01, Publication Date: 1986-05-06.
• "Steroid Dehydrogenation Process Intermediates" : Application No: 07/520,991, Publication No. U.S. Patent 5116983, Application Date: 1990-05-08, Publication Date: 1992-05-26.   
• "Dehydrogenation of Azasteroids", Application No: 07/478,064, Publication No: U.S. Patent 5084574, Application Date: 1990-02-07, Publication Date: 1992-01-28.   
• "Preparation of 4-Azo-chol-1-ene-3, 20-dione derivatives as testosterone reductase inhibitors" Application No: EP19890311066 19891026, Publication No: European Patent EP 0367502 (A1), Publication Date: 1990-05-09.
• "Process for the dehydrogenation of 3-oxo steroids (and especially 3-oxo-4aza steroids) in the 1,2-position using quinones and silylating agents, and quinone-steroid adduct intermediates" Application No: EP19880305926 19880627, Publication No, European Patent EP-298652 (A2), Publication Date: 1989-01-11.
• “Amphoteric copolymer derived from vinylpyridine and acetoxystyrene” Application No: 08/003,350, Publication No: US Patent 5232995, Application Date: 1993-01-12, Publication Date: 1993-08-03.
• "Amphoteric Copolymer Derived from Vinylpyridine and Acetoxystyrene" Application No: 07/968,741, Publication No. U.S. Patent: 5210149, Application Date: 1992-10-30, Publication Date: 1993-05-11.
• "Amphoteric Copolymer Derived from Vinylpyridine and Acetoxystyrene" Application No: 08/042,358, Publication No: U. S. Patent: 5304610, Application Date: 1993-04-02, Publication Date: 1994-04-19.
• “Amphoteric copolymer derived from vinylpyridine & acetoxystyrene | Copolymere amphotere derive de la vinylpyridine et de l'acetoxystyrene” Publication No: Canadian Patent CA 2158555, Application Date: 1994-03-23, Publication Date: 1994-10-13.
• “Amphoteric copolymer derived from vinylpyridine & acetoxystyrene” Application No: PCT/US1994/003133, Publication No: WO 1994/022929, Application Date: 1994-03-23, Publication Date: 1994-10-13.
• “Amphoteric copolymer derived from vinylpyridine & acetoxystyrene” Application No: EP19940914722 19940323, Publication No: European Patent EP 0691990 (A1), Publication Date: 1996-01-17.
• “Methods for synthesizing benign prostatic hypertropic agents and their intermediates | Methode de synthese d'agents prostatiques benins hypertrophiques et de leurs intermediaires” Application No: 615350, Publication No: Canadian Patent CA 1326013, Application Date: 1989-09-29, Publication Date: 1994-01-11.
• “Dehydrogenation process | Procede de deshydrogenation” Application No: 570228, Publication No: Canadian Patent CA 1331601, Application Date: 1988-06-23, Publication Date: 1994-08-23.
• “Dehydrogenation process and intermediates” Application No: Singapore Patent 1995911020.
• "Precipitation-Induced Asymmetric Transformation of Chiral Alpha-Amino Acids and salts thereof" Application No: European Patent EP19920300648 19920124, Publication No European Patent EP-0499376 (A1), Publication Date: 1992-08-19.
• "Racemization of an Enantiomerically Enriched a-Aryl Carboxylic Acid" Application No: 07/985,083, Publication No: US Patent; 5332834, Application Date: 1992-12-02, Publication Date: 1994-07-26.
• "Selective Precipitation of alpha arylcarboxylic acid salts" Application No: 08/139,245, Publication No U.S. Patent: 5380867, Application Date: 1993-10-19, Publication Date: 1995-01-10.
• “Selective Precipitation of alpha arylcarboxylic acid salts” Application No: 08/257,412, Publication No. U.S. Patent 5399707, Application Date: 1994-06-10, Publication Date: 1995-03-21.
• “Selective precipitation of (a)-aryl carboxylic acid salts.” Application No: EP19940903318 19931129, Publication No: European Patent EP 0672029 (A1), Publication Date: 1995-09-20.
• "Process for the Productton of Calcium Salts of Hydantoic Acid. Application No: 08/016,628, Publication No: U.S. Patent 5338859, Application Date: 1993-02-12, Publication Date: 1994-08-16.
• "Process for preparing cyclic ketones" Application No: 08/334,822,  Publication No: US Patent 5489712, Application Date: 1994-11-04, Publication Date: 1996-02-06.
• “Process for preparing cyclic ketones” Application No: PCT/US1995/013760, Publication No: WO 1996/014284, Application Date: 1995-10-25, Publication Date: 1996-05-17.
• “Process for preparing cyclic ketones” Application No: EP19950939583 19951025, Publication No: European Patent EP 0789680 (A1), Publication Date: 1997-08-20.
• “Process for the preparation of dialkali metal cromoglycates” Application No: 08/271,804, Publication No: US Patent 5508451, Application Date: 1994-07-07, Publication Date: 1996-04-16.
• “Preparation of 4-quinazolinones from N-acyl-b-aminoacids” Application No: 08/596,794, Publication No: US Patent 5739330, Application Date: 1996-02-05, Publication Date: 1998-04-14.
• “Process for preparing quinazolones” Application No: PCT/US1997/001861, Publication No: WO 1997/028134, Application Date: 1997-01-30, Publication Date: 1997-08-07.
• “Preparation of 5,6-dihydro-3H-pyrimidin-4-one derivatives” Application No: 08/595,885, Publication No: US Patent 5763608, Application Date: 1996-02-05, Publication Date: 1998-06-09.
• “Application No: PCT/US1997/001860, Publication No: WO 1997/028132, Application Date: 1997-01-30, Publication Date: 1997-08-07.
• “Three step process for preparing anthranilic acids from aniline” U.S. Patent 96-593536.
• “Process for preparing anthranilic acids” Application No: PCT/US1997/001862, Publication No: WO 1997/028118, Application Date: 1997-01-30, Publication Date: 1997-08-07.
•  “Precipitation-induced asymmetric transformation of chiral alpha-amino acids and salts thereof | Transformation d'acides chiraux du type alpha-amino et de leurs sels, induits par la precipitation” Publication No: Canadian Patent CA 2060051, Application Date: 1992-01-27.
• “Methods of synthesizing benign prostatic hypertrophic agents” Application No: Hong Kong HK 98101898, Publication No: 1002707, Application Date: 1998-03-09, Publication Date: 1998-09-11.
• “Process for azole antifungal intermediate” Document No: 6326509, Application No: 09/568,874, Publication No: US Patent 6326509, Application Date: 2000-05-09, Publication Date: 2001-12-04.
• “Improved process for azole antifungal intermediate” Document No: 2000/071498, Application No: PCT/US2000/012740, Publication No: WO/2000/071498, Application Date: 2000-05-10, Publication Date: 2000-11-30.
•  “Method of producing organic compounds in presence of oxyethylene ether catalyst and in a solvent minimized environment” Document No: 6969775, Application No: 10/666,543, Publication No: US Patent 6969775, Application Date: 2003-09-19, Publication Date: 2005-11-29.
• “Method of producing organic compounds in presence of oxyethylene ether catalyst and in a solvent minimized environment” Document No: 20040138509, Application No: 666543, Publication No: US Patent 20040138509, Application Date: 2003-09-19, Publication Date: 2004-07-15.
•  “Preparation of 4-(2-Bromoethoxy)phenol”. Patent applied in collaboration with Johnson & Johnson (2003 pending).
• “Method for preparing pyrrolotriazine compounds via in situ amination of pyrroles” Document No: 20060229449, Application No: 396888 Publication No US Patent, Application Date: 2006-04-03 Publication Date: 2006-10-12   
• “Method of preparation of nitroaminopyridine compounds” Document No: 2007/019259 Application No: PCT/US2006/030347 Publication No: WO/2007/019259 Application Date: 2006-08-02 Publication Date: 2007-02-15.
• “Method of preparation of nitroaminopyridine compounds” Document No: 20070032657, Application No: 492730, Publication No: US Patent 20070032657, Application Date: 2006-07-25, Publication Date: 2007-02-08.
• “One-pot reductive acetamidation of aryl nitro compounds”, Document No: 2006/023763, Application No: PCT/US2005/029611, Publication No: WO/2006/023763, Application Date: 2005-08-18, Publication Date: 2006-03-02.    
• “One-pot reductive acetamidation of aryl nitro compounds”, Document No: 20060052638, Application No: 208474, Publication No: US Patent 20060052638, Application Date: 2005-08-19, Publication Date: 2006-03-09.
• "One Pot Reductive Acetaminidation of Aryl Nitro Compounds", Document No: 7173152, Application No: 11/208,474 Publication No: US Patent 7173152 Application Date: 2005-08-19 Publication Date: 2007-02-06
• “Purification process using co-crystal approaches”-US provisional application 60/827,259 on 28 Sep 2006
• “Process for preparing fosphenytoin” Document No: 20070249563, Application No: 737783, Publication No: US Patent 20070249563, Application Date: 2007-04-20, Publication Date: 2007-10-25.
• “Method for preparing pyrrolotriazine compounds via in situ amination of pyrroles” Document No: 7534882Publication No: US Patent 7534882. Application Date: 2006-04-03. Publication Date: 2009-05-19.

III. Published Abstracts and Meeting Proceedings

• "Efficient Asymmetric Alkylations via Chiral Phase-Transfer Catalysis". For presentation at : American Chemical Society 190th National Meeting, Chicago, Illinois,9/8/85-9/13/1985.
• "Quarternary Ammonium Ions Derived From Cinchona Alkaloids as Chiral Phase-Transfer Alkylation Catalysts: Appilations and mechanisms".: Hetrocyclic Chemistry 10th International Congress, Waterloo, Ontario, Canada, 8/11/85-8/16/1985.
• "Efficient Asymmetric Alkylations via Chiral Phase-Transfer Catalysis. A Novel Dual Catalysis".: Organic Reactions Catalysis Society Eleventh Meeting, Savannah, Georgia, 4/6/86-4/8/1986.
• "Recent  Mechanistic Studies on The Mitsunobo reaction and DDQ-Mediated double bond introduction".: Gordon Research Conference on Organic Reactions and Processes, New Hampshire, 7/13/87-7/18/1987.
• "Quinone Oxidation in Synthesis;Fascination New Mechanistic Aspects".: U.of Texas at Austin, Austin, Texas, November 5, 1987.
• "Silicon Assisted Quinone Oxidation: Mechanisms and application to aza-steroid synthesis".: U. of Houston, Houston, Texas, November 6, 1987.
• "Quinone Oxidation: Mechanism and application in steroid synthesis".: Texas A&M Univ. College Station, Texas, November 9, 1987.
• "Silylation Mediated Quinone oxidation".: Merck-Bucknell Symposium, March 16, 1988.
• "Oxidation of Lactum Derived TMS-Imidates With Quinones Proceeds Via Unprecedented Quinone-Substrate Adducts".: Heterocyclic Chemistry 12th International Congress, Jerusalem, Israel, 8/13/89-8/17/1989.
• "Synthesis of ∆1-4-Aza Steroids via Silylation Mediated Quinone Oxidation".: Lakeland Heterocyclic symposium, Grasmere.Royal Society of Chemistry: Perkin Division May 4-8 1989.
• "Quinone Oxidation of TMS Imidates and Enolethers Proceeds via Single Electron Tranlfer".:32nd IUPAC Congress Stockholm,2-7 August 1989.
• “Development of Finastride”.: 2001 4th Annual Howard Radwin Urology Conference San Antonio Medical Center. Texas October 19-20, 2001
• “Environmentally Friendly Solvent-Free Processes: Preparation of Nitro Alcohols, A Class of Valuable Drug Intermediates by Henry Reaction”.: American Chemical Society 57th Southwest Regional Meeting October 17-20, 2001, San Antonio, Texas.
• “Environmentally Friendly Solvent Free Processes: Application of a novel surfactant induced dual catalysis in Henry Reaction”. 6th Annual Green Chemistry and Engineering Conference Washington, D.C. June 24-27, 2002.
• “Environmentally Friendly Solvent Free Processes: Application of a novel surfactant induced dual catalysis in the Preparation of Pharmaceutical Intermediates”. Tenth Annual Coastal Bend Environmental Conference, Kingsville, Texas, October 30-Nov 1, 2002.
• “Bridging Process Research and Development: from Academia to Industry”
• Pharm-Eco John Matthey, February 20, 2002.
• “Bridging Green Chemistry to Industry” Sepracor Inc; February 20, 2002.
• “Green Chemistry in Texas A&M Kinsville”. Johnson & Johnson Pharmaceutical Research & Development. March 28, 2003.
• “Process Research and Development: From Academia to Industry”. University of Texas Medical Branch, Galveston Medical Center. March 30, 2003.
• “Intermediacy in Quinone Oxidation” The University of Texas-Pan American. April 10, 2003.
• “Applications in Green Technology” October 22, 2003. Environmental Engineering Seminar. Texas A&M Kingsville.
• “Temperature Selective Diastereo-Recognition (TSD): Enantiomeric Ibuprofen via Environmentally Benign Selective Crystallization”. South Texas Section, American Chemical Society, Second Research Symposium, Kingsville, Texas, November 21, 2003.
• “Process Development studies of a BPH Candidate” Ranbaxy Pharmaceutical, Delhi, India, January 6, 2004.
• “Drug Developmental studies of Azasteroids” Astra Zeneca  Pharmaceutical, Bangalore, India, January 9, 2004.
• “Process Developmental Studies of Pharmaceutical Intermediate in Texas A&M University-Kingsville, Dr. Reddy’s Lab, India, January 12, 2004.
• “The Role of Bristol-Myers Squibb in Educating the Next Generation: Process R&D at Texas A&M Kingsville. Part I
• Development of Proscar. Part II”. Bristol Myers Squibb Pharmaceutical Research Institute, New Brunswick, NJ, February 20, 2004.
• "Process Research and Development in Texas A&M Kingsville: Educating the Next Generation". Novartis Pharmaceutical. East Hanover, NJ, February 19, 2004.
• “Application of Quinone oxidation in developing and alfa reductase inhibitor candidate”. Ambion Pharmaceutical, Austin Texas. April 1, 2004.
• “Development of a BPH candidate: Synthesis of Finasteride” University of Texas at Austin, Austin, Texas April 2, 2004.
• “Educating next generation of Process Chemists in Academia” ACS Petroleum Research Fund Presidential Symposium, 228th meeting of the American Chemical Society, Philadelphia, August 2004.
• “Green Technology in Pharmaceutical Process Development”. Abstracts, 60th Southwest Regional Meeting of the American Chemical Society, Fort Worth, TX, United States, September 29-October 4  (2004), SEPT04-268.  Publisher: American Chemical Society,  Washington, D. C.
• “Enantiomeric Ibuprrofen Via Environmentally Benign Temperature Selective Diastereo-Recognition (Tsd)”. Abstracts, 60th Southwest Regional Meeting of the American Chemical Society, Fort Worth, Texas, United States, September 29-October 4  (2004), SEPT04-076.  Publisher: American Chemical Society, Washington, D. C.
• “Application of Green Technology in Pharmaceutical Process Development” IUCCP symposium October 18-20, 2004; College Station, Texas.
• “Green Chemistry in Organic Synthesis” Texas Tech University, Lubbock, Texas February 15, 2005.
• “Pharmaceutical Process Development” Texas Tech University, Lubbock, Texas February 15, 2005.
• “Green technology in pharmaceutical process development: Application in the synthesis of Acetaminophen, Ibuprofen and heterocycles” 229th meeting of the American Chemical Society, San Diego, March 2005.
• “Evolution of a BPH candidate in the Pharmaceutical Drug Development” Chemistry/Biological Sciences, Department of Chemistry, The University of Arizona, April 8, 2005.
• “Green Chemistry as part of Process Research and Development at Texas A&M-Kingsville”. Chemistry/Biological Sciences, Department of Chemistry, The University of Arizona, April 8, 2005.
• “Commonalities and Differences in Industry and Research Careers” Luis Stokes Alliance for Minority Participation Mini Symposium, Kingsville, Texas, November 4, 2005.
• “Pharmaceutical Process Research and Development through Green Chemistry at Texas A&M Kingsville, Roger Adams Lab, U. of Illinois. November 14, 2005.
• “Development of the BPH Drug: Finasteride” Noyes Lab. U. of Illinois. November 14, 2005.
• “Educating the Next Generation of Process Chemists in an Undergraduate Program” Merck & Co, Rahway, NJ. November 11, 2005.
• “Green Chemistry: Efficiency in Pharmaceutical Development” Focus Indian Conference on Pharmaceutical R&D Efficiencies-Integrating Global Strategic Partnerships. Hyderabad, India. March 15-17, 2006.
• “Application of Green Technology in Pharmaceutical Process Development” Current Research Trends and Developments in Heterocyclic Chemistry. Osmania University, Hyderabad, India. March 17-18, 2006.
• “Essentials of Process Research & Development”. University of Texas at Arlington, Arlington, Texas, May 9, 2006.
• “The Application of Green Technology in Pharmaceutical Process Development”. The 4th Annual Congress of International Drug Discovery Science and Technology. Northwestern University, Xi-An, China.  May 31-June 2, 2006.
• “Green Technology in Pharmaceutical Process Development” Developing Chemical Processes for Active Pharmaceutical Ingredients. Scientific Update Conference, N. C. L. Pune, India. December 13-14. 2006.
• “Green Chemistry” Chemistry & Life. Osmania University College for Women Koti, Hyderabad, India. January 5, 2007.
• “Green Technology in Pharmaceutical Development” National Conference on Drug Designing & Synthesis. Dr. Ambedkar College, Nagpur, India. Janurary 19-20, 2007.
• "Total Synthesis of (-)-Galanthamine Hydrobromide” 234th American Chemical Society Conference, Boston (19-23 August), 2007.
• “Principles of Green Chemistry in API synthesis” Green Chemistry in Conference on Green Chemistry in Drug Synthesis, Department of Chemistry, MNR Degree and PG College Hyderabad India. January 29, 2008,
• “Application of Green Principles in API Synthesis” National Symposium on Emerging Trends in Medicinal Chemistry, India – A Global Hub” Department of Chemistry, C.K.M. Arts & Science College, Warangal, Hyderabad, India. February 2-3, 2008.
• "Crystal engineering: Application in the development of Finasteride" Developing Chemical Processes for APIs Scientific Update Conference, February 14-15 2008, Hyderabad, India
• “De novo synthesis of Rimonabant and its regioisomer” 9th Annual Florida Heterocyclic and Synthetic IUPAC-Sponsored Conference Register online for FloHet IX conference. March 9th - 12th, 2008. Gainesville. Fl.
• “Green Chemistry and the Global Pharmaceutical Industry” CHEMICAL SCIENCES ROUNDTABLE, May 19-20, 2008. The National Academies, Keck Building. Washington, DC.
• “Green chemistry in the Generic Pharmaceutical Industry” 2nd International Symposium on Green Processing in the Pharmaceutical & Fine Chemical Industries May 29-30, 2008.  Yale University, New Haven, Connecticut, USA

Hobbies:  Watching Football (Especially DALLAS COWBOYS)